UBS Group AG Reduces Holdings in Alpha Teknova, Inc. $TKNO

UBS Group AG trimmed its stake in Alpha Teknova, Inc. (NASDAQ:TKNO) by 50.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 737,265 shares of the company’s stock after selling 764,879 shares during the period. UBS Group AG owned approximately 1.38% of Alpha Teknova worth $2,802,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Alpha Teknova in the 2nd quarter valued at $29,000. JPMorgan Chase & Co. boosted its stake in Alpha Teknova by 123.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 8,163 shares of the company’s stock worth $40,000 after purchasing an additional 4,504 shares during the period. Larson Financial Group LLC boosted its stake in Alpha Teknova by 58.5% during the 3rd quarter. Larson Financial Group LLC now owns 9,387 shares of the company’s stock worth $58,000 after purchasing an additional 3,464 shares during the period. Sherbrooke Park Advisers LLC acquired a new stake in Alpha Teknova during the 3rd quarter worth $94,000. Finally, New York State Common Retirement Fund acquired a new stake in Alpha Teknova during the 2nd quarter worth $96,000. 13.81% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Teknova in a research note on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $8.00.

Alpha Teknova Price Performance

Shares of NASDAQ:TKNO opened at $3.89 on Tuesday. The stock has a market cap of $208.54 million, a P/E ratio of -12.16 and a beta of 0.47. The firm has a fifty day moving average price of $3.21 and a 200 day moving average price of $3.45. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.59 and a quick ratio of 3.60. Alpha Teknova, Inc. has a 1-year low of $1.91 and a 1-year high of $6.68.

Alpha Teknova (NASDAQ:TKNO) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. The company had revenue of $11.08 million during the quarter, compared to the consensus estimate of $10.23 million. Alpha Teknova had a negative net margin of 41.07% and a negative return on equity of 24.32%.

Insider Buying and Selling

In other news, CEO Stephen Gunstream acquired 26,000 shares of the business’s stock in a transaction on Friday, March 6th. The stock was bought at an average price of $2.15 per share, for a total transaction of $55,900.00. Following the transaction, the chief executive officer owned 269,497 shares in the company, valued at $579,418.55. This represents a 10.68% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 12.50% of the company’s stock.

Alpha Teknova Profile

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.